Table 2.
The clinical characteristics of 20 cases diagnosed with de novo or R/R AML
| Patient No | Age (yrs) | Gender | WBC (× 109) | LDH (U/L) | Blasts (%) | Karyotype | Molecular features |
|---|---|---|---|---|---|---|---|
| 1 | 68 | F | 4.85 | Normal | 24 | Normal | / |
| 2 | 66 | M | 48.34 | High | 36 | 46, XY, t (2;22) | TET2 |
| 3 | 55 | F | 21.38 | High | 69 | Complex | NPM1, TET2, ASXL1 |
| 4 | 57 | M | 47.34 | High | 74 | 46, XY, t (8;21) | AML-ETO |
| 5 | 32 | M | 324.4 | High | 92 | 46, XX, inv (16) | CBFB-MYH11 |
| 6 | 60 | M | 52.12 | Normal | 43 | Normal | CEBPA, TET2 |
| 7 | 64 | F | 16.12 | High | 62 | Normal | IDH, Runx1 |
| 8 | 28 | F | 15.63 | High | 52 | 46, XY, inv (16) | CBFB-MYH11, ASXL1, CEBPA |
| 9 | 44 | M | 23.56 | Normal | 46 | Normal | / |
| 10 | 9 | F | 581.8 | High | 92 | ND | / |
| 11 | 11 | M | 48.65 | High | 57 | Normal | / |
| 12 | 6 | F | 231.2 | High | 78 | Complex | FLT3-ITD |
| 13 | 5 | M | 180.3 | High | 43 | 46, XX, del (14) (q32) | / |
| 14 | 10 | F | 53.1 | High | 64 | Normal | c-KIT |
| 15 | 58 | M | 45.3 | Normal | 36 | 45, XY, − 7 | TP53 |
| 16 | 46 | F | 153.2 | High | 76 | Complex | FLT3-ITD |
| 17 | 32 | F | 201.2 | High | 91 | 46, XX | ASXL1 |
| 18 | 40 | M | 53.4 | High | 45 | 45, XY, − 5 | / |
| 19 | 19 | M | 75.3 | High | 58 | 46, XY | DNMT3A |
| 20 | 23 | F | 121.5 | Normal | 48 | Normal | CEBPA |